Target intelligence / Profile preview

Vacuolar protein sorting-associated protein 16B (VPS16B) (VPS16B)

Target
VPS16B
Molecular classification
Vesicle-tethering protein, CHEVI complex subunit, SM-binding protein
01

Overview

Vacuolar protein sorting-associated protein 16B (VPS16B), also known as VIPAR or SPE-39, is a critical regulator of intracellular vesicle trafficking and organelle biogenesis. It functions primarily by forming a stable complex with the Sec1/Munc18 (SM) protein VPS33B, which together facilitate the docking and fusion of vesicles with target membranes, such as late endosomes and lysosomes [2, 13]. In megakaryocytes, this complex is essential for the biogenesis of alpha-granules, which store proteins vital for blood clotting and wound healing [2, 5]. Mutations in the VIPAS39 gene, which encodes VPS16B, lead to Arthrogryposis, Renal dysfunction, and Cholestasis (ARC) syndrome type 2, a severe multisystem disorder characterized by the absence of platelet alpha-granules, liver disease, and renal defects [8, 14]. The protein also plays a significant role in maintaining apical-basolateral polarity in epithelial cells by regulating the trafficking of apical proteins [11, 12]. While there are currently no approved drugs targeting VPS16B, it is a significant focus of research for understanding inherited platelet disorders and developing potential gene therapies for ARC syndrome [7, 9].

Other names
VIPAS39VIPARSPE-39SPE39hSPE-39Spermatogenesis-defective protein 39 homologVPS33B-interacting protein, apical-basolateral polarity regulator
02

Mechanism of action

Forms a complex with VPS33B to facilitate SNARE-mediated vesicle fusion and protein sorting, specifically during the maturation of alpha-granules in megakaryocytes and the maintenance of apical-basolateral polarity in epithelial cells.

03

Biological functions

Vesicle-mediated transportPlatelet alpha-granule biogenesisApical-basolateral polarity regulationEndosome-to-lysosome traffickingProtein sorting
04

Disease associations

Arthrogryposis, renal dysfunction, and cholestasis syndrome 2 (ARC2)Platelet alpha-granule deficiencyBleeding disorderCholestasisRenal tubular acidosis
05

Safety considerations

Severe multisystemic toxicity (ARC-like symptoms) if inhibitedBleeding riskLiver and kidney dysfunction
06

Biomarkers

VIPAS39 gene mutationsAbsence of platelet alpha-granulesReduced VPS16B protein expressionElevated serum bile acids

Beyond the preview

Go deeper on Vacuolar protein sorting-associated protein 16B (VPS16B) (VPS16B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vacuolar protein sorting-associated protein 16B (VPS16B) (VPS16B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call